|Table of Contents|

Application and prospect of circulating tumor cells in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
655-659
Research Field:
Publishing date:

Info

Title:
Application and prospect of circulating tumor cells in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer
Author(s):
Jin Xiaohu; Zhao Yi
Department of Breast Surgery，Shengjing Hospital of China Medical University，Liaoning Shenyang 110000，China.
Keywords:
breast cancer; circulating tumor cells; neoadjuvant chemotherapy
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.04.031
Abstract:
With the in-depth study of the pathogenesis and disease progression of breast cancer,neoadjuvant chemotherapy has become the preferred treatment for patients with inflammatory breast cancer,locally advanced breast cancer and optional early surgical treatment.Therefore,the evaluation of the efficacy of neoadjuvant chemotherapy has become a key link in the treatment.Imaging data is the preferred method in clinic,but the application of serological indexes is rare.Circulating tumor cells (CTCs),as an increasingly mature serological marker,have the advantages of convenient sampling,easy detection method,small body trauma,repeatable monitoring and so on.Compared with traditional imaging data,CTCs can detect micrometastasis earlier and have no radiation damage and other advantages,so it has a broad application prospect.This article reviews the value of CTCs in the evaluation of neoadjuvant chemotherapy for breast cancer.

References:

［1］Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
［2］Masood S.Neoadjuvant chemotherapy in breast cancers［J］.Women's Health,2016,12(5):480-491.
［3］Selli C,Sims AH.Neoadjuvant therapy for breast cancer as a model for translational research［J］.Breast Cancer:Basic and Clinical Research,2019(13):1178223419829072.
［4］Apuri S.Neoadjuvant and adjuvant therapies for breast cancer［J］.Southern Medical Journal,2017,110(10):638-642.
［5］Cho JK,Lee GJ,Kim HD,et al.Differential impact of circulating tumor cells on disease recurrence and survivals in patients with head and neck squamous cell carcinomas:An updated meta-analysis［J］.PloS One,2018,13(9):e0203758.
［6］Tong B,Xu Y,Zhao J,et al.Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy［J］.Oncotarget,2017,8(49):86615-86624.
［7］Chou WC,Wu MH,Chang PH,et al.A prognostic model based on circulating tumour cells is useful for identifying the poorest survival outcome in patients with metastatic colorectal cancer［J］.International Journal of Biological Sciences,2018,14(2):137-146.
［8］Palmirotta R,Lovero D,Cafforio P,et al.Liquid biopsy of cancer:A multimodal diagnostic tool in clinical oncology［J］.Therapeutic Advances in Medical Oncology,2018(10):1758835918794630.
［9］Bardelli A,Pantel K.Liquid biopsies,what we do not know (yet)［J］.Cancer Cell,2017,31(2):172-179.
［10］Maheswaran S,Haber DA.Circulating tumor cells:A window into cancer biology and metastasis［J］.Current Opinion in Genetics & Development,2010,20(1):96-99.
［11］Soler A,Cayrefourcq L,Mazel M,et al.Epcam-independent enrichment and detection of viable circulating tumor cells using the epispot assay［J］.Methods in Molecular Biology,2017(1634):263-276.
［12］Kim MY,Oskarsson T,Acharyya S,et al.Tumor self-seeding by circulating cancer cells［J］.Cell,2009,139(7):1315-1326.
［13］Zhang C,Guan Y,Sun Y,et al.Tumor heterogeneity and circulating tumor cells［J］.Cancer Letters,2016,374(2):216-223.
［14］Markiewicz A,Zaczek AJ.The landscape of circulating tumor cell research in the context of epithelial-mesenchymal transition［J］.Pathobiology:Journal of Immunopathology,Molecular and Cellular Biology,2017,84(5):264-283.
［15］Markiewicz A,Nagel A,Szade J,et al.Aggressive phenotype of cells disseminated via hematogenous and lymphatic route in breast cancer patients［J］.Translational Oncology,2018,11(3):722-731.
［16］Markiewicz A,Topa J,Nagel A,et al.Spectrum of epithelial-mesenchymal transition phenotypes in circulating tumour cells from early breast cancer patients［J］.Cancers,2019,11(1):59.
［17］Han D,Chen K,Che J,et al.Detection of epithelial-mesenchymal transition status of circulating tumor cells in patients with esophageal squamous carcinoma［J］.Bio Med Research International,2018(2018):7610154.
［18］Papadaki MA,Kallergi G,Zafeiriou Z,et al.Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer［J］.BMC Cancer,2014(14):651.
［19］Kanwar N,Hu P,Bedard P,et al.Identification of genomic signatures in circulating tumor cells from breast cancer［J］.International Journal of Cancer,2015,137(2):332-344.
［20］Aktas B,Tewes M,Fehm T,et al.Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients［J］.Breast Cancer Research,2009,11(4):R46.
［21］Kasimir-Bauer S,Hoffmann O,Wallwiener D,et al.Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells［J］.Breast Cancer Research,2012,14(1):R15.
［22］Hardingham JE,Grover P,Winter M,et al.Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress［J］.Molecular Medicine,2015,21(Suppl 1):S25-31.
［23］Ignatiadis M,Lee M,Jeffrey SS.Circulating tumor cells and circulating tumor DNA:Challenges and opportunities on the path to clinical utility［J］.Clinical Cancer Research,2015,21(21):4786-4800.
［24］WANG YJ,GUO X,WANG XF.Detection methods and clinical applications of circulating tumor cells in breast cancer［J］.Chinese Journal of Clinical Laboratory Management,2017,5(02):78-80.［王玉洁,国霞,王晓飞.乳腺癌循环肿瘤细胞检测方法及临床应用［J］.中华临床实验室管理电子杂志,2017,5(02):78-80.］
［25］Kallergi G,Aggouraki D,Zacharopoulou N,et al.Evaluation of alpha-tubulin,detyrosinated alpha-tubulin,and vimentin in CTCs:Identification of the interaction between CTCs and blood cells through cytoskeletal elements［J］.Breast Cancer Research,2018,20(1):67.
［26］Ramirez AB,Bhat R,Sahay D,et al.Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining,image acquisition,and single cell retrieval and analysis［J］.BMC Cancer,2019,19(1):220.
［27］Krebs MG,Hou JM,Ward TH,et al.Circulating tumour cells:Their utility in cancer management and predicting outcomes［J］.Therapeutic Advances in Medical Oncology,2010,2(6):351-365.
［28］LIU ZY,LI BJ.Efficacy of neoadjuvant chemotherapy on breast cancer and dynamic changes of circulating tumor cells［J］.Chin J Clin Oncol,2013,40(23):1431-1435.［刘志勇,李宝江.乳腺癌新辅助化疗中循环肿瘤细胞的动态变化及疗效观察［J］.中国肿瘤临床,2013,40(23):1431-1435.］
［29］ZHANG JL,YAO Q,CHEN JH,et al.Effects of Herceptin on circulating tumor cells in HER-2 positive early breast cancer［J］.Modern Oncology,2013,21(02):279-281.［张聚良,姚青,陈江浩,等.曲妥珠单抗对HER-2阳性早期乳腺癌外周血循环肿瘤细胞的影响［J］.现代肿瘤医学,2013,21(02):279-281.］
［30］Wang C,Mu Z,Chervoneva I,et al.Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer［J］.Breast Cancer Research and Treatment,2017,161(1):83-94.
［31］Cristofanilli M,Pierga JY,Reuben J,et al.The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC):International expert consensus paper［J］.Critical Reviews in Oncology/Hematology,2019(34):39-45.
［32］Zhang L,Riethdorf S,Wu G,et al.Meta-analysis of the prognostic value of circulating tumor cells in breast cancer［J］.Clinical Cancer Research,2012,18(20):5701-5710.
［33］Smerage JB,Barlow WE,Hortobagyi GN,et al.Circulating tumor cells and response to chemotherapy in metastatic breast cancer:Swog s0500［J］.Journal of Clinical Oncology,2014,32(31):3483-3489.
［34］Kaigorodova EV,Savelieva OE,Tashireva LA,et al.Heterogeneity of circulating tumor cells in neoadjuvant chemotherapy of breast cancer［J］.Molecules,2018,23(4):727.
［35］Ignatiadis M,Rack B,Rothe F,et al.Liquid biopsy-based clinical research in early breast cancer:The eortc 90091-10093 treat CTC trial［J］.European Journal of Cancer,2016(63):97-104.
［36］Aktas B,Kasimir-Bauer S,Muller V,et al.Comparison of the HER-2,estrogen and progesterone receptor expression profile of primary tumor,metastases and circulating tumor cells in metastatic breast cancer patients［J］.BMC Cancer,2016(16):522.
［37］Schramm A,Friedl TW,Schochter F,et al.Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer:Concept of the detect study program［J］.Archives of Gynecology and Obstetrics,2016,293(2):271-281.
［38］Boral D,Vishnoi M,Liu HN,et al.Molecular characterization of breast cancer CTCs associated with brain metastasis［J］.Nature Communications,2017,8(1):196.
［39］Loibl S,von Minckwitz G,Schneeweiss A,et al.PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer［J］.Journal of Clinical Oncology,2014,32(29):3212-3220.
［40］Majewski IJ,Nuciforo P,Mittempergher L,et al.PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer［J］.Journal of Clinical Oncology,2015,33(12):1334-1339.
［41］Seo Y,Park YH,Ahn JS,et al.PIK3CA mutations and neoadjuvant therapy outcome in patients with human epidermal growth factor receptor 2-positive breast cancer:A sequential analysis［J］.Journal of Breast Cancer,2018,21(4):382-390.
［42］Ma F,Li Q,Chen S,et al.Phase I study and biomarker analysis of pyrotinib,a novel irreversible pan-ERBB receptor tyrosine kinase inhibitor,in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer［J］.J Clin Oncology,2017,35(27):3105-3112.

Memo

Memo:
辽宁省自然科学基金资助项目(编号：2015020544)
Last Update: 2019-12-26